New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo ... s that it was awaiting complete data from the study. “Treatment of obesity is about improving health, well ...

People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday.

Participants using Zepbound lost 50.3 lbs (22.8 kg) and participants on Wegovy lost 33.1 lbs (15.0 kg) SURMOUNT-5 compared Zepbound, a dual GIP and GLP-1 receptor agonist, to Wegovy, a mono GLP-1 ...

In June, Eli Lilly released additional data from the studies showing that Zepbound helped resolve OSA in almost half of patients. The first study examined the weekly injection in adults with ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

Eli Lilly and Company ... its popular obesity drug, Zepbound (tirzepatide) outperformed rival Novo Nordisk’s NVO Wegovy (semaglutide) in a weight-loss head-to-head study. In the phase IIIb ...

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...

06:47 EST Lilly says Zepbound superior to Novo’s Wegovy weight loss in head-to-head trial Don't Miss our Black Friday Offers: Unlock your investing potential with TipRanks Premium - Now At 40% OFF!

Low blood sugar ... that future study results will be consistent with study results to date, that Zepbound will receive additional regulatory approvals, or that Lilly will execute its strategy ...

Participants using Zepbound ... we conducted this study to help health care providers and patients make informed decisions about treatment choice," said Leonard C. Glass, MD, FACE, senior vice ...